Cargando…

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone...

Descripción completa

Detalles Bibliográficos
Autor principal: Funder, John W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796852/
https://www.ncbi.nlm.nih.gov/pubmed/24133375
http://dx.doi.org/10.2147/IBPC.S13783